EVIDENCE WATCH
A review and assessment of recent clinical trial data

Lung cancer
RANDOMIZED CLINICAL TRIAL OF ADJUVANT CHEMOTHERAPY WITH PACLITAXEL AND CARBOPLATIN FOLLOWING RESECTION IN STAGE IB NON-SMALL CELL LUNG CANCER (NSCLC): REPORT OF CANCER AND LEUKEMIA GROUP B (CALGB) PROTOCOL 9633.

A PROSPECTIVE RANDOMIZED TRIAL OF ADJUVANT VINORELBINE (VIN) AND CISPLATIN (CIS) IN COMPLETELY RESECTED STAGE 1B AND II NON-SMALL CELL LUNG CANCER (NSCLC) INTERGROUP JBR.10.

Breast cancer
GLOBAL PHASE III STUDY OF GEMCITABINE PLUS PACLITAXEL (GT) VS PACLITAXEL (T) AS FRONTLINE THERAPY FOR METASTATIC BREAST CANCER (MBC): FIRST REPORT OF OVERALL SURVIVAL.

 

To view the clinical trial data of the above topics click here (pdf format)
Back to Top of Page 

 

 
 
 
This issue of Oncology Exchange provides overviews of important clinical trial data presented at the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO), held in New Orleans, LA, June 5–9, 2004. Leading Canadian experts offer commentary and clinical interpretations.
 
© Parkhurst Publishing Privacy Statement
Legal Terms of Use
 Site created by Spin Design (514) 995-4398